Effect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer Stephen J. Wigmore, Matthew D. Barber, James A. Ross, Michael J. Tisdale, and Kenneth C. H. Fearon. Nutrition and Cancer 36(2):177-184, 2000. Abstract Eicosapentaenoic acid (EPA) has been shown to modulate aspects of the inflammatory response that may contribute to weight loss in cancer. This study aimed to evaluate the acceptability and effects of oral supplementation with high-purity EPA in weight-losing patients with advanced pancreatic cancer. Twenty-six patients were entered into the study. EPA (95% pure) was administered as free acid starting at 1 g/day; the dose was increased to 6 g/day over four weeks, and then a maintenance dose of 6 g/day was administered. Patients were assessed before EPA and at 4, 8, and 12 weeks while receiving EPA, for weight, body composition, hematologic and clinical chemistry variables, acute-phase protein response, and performance status. Overall survival was noted. Supplementation was well tolerated, with only five patients experiencing side effects possibly attributable to the EPA. Before starting EPA, all patients had been losing weight at a median rate of 2 kg/mo. In general, after EPA supplementation, weight was stable. After four weeks of EPA supplementation, patients had a median weight gain of 0.5 kg (p = 0.0009 vs. rate of weight loss at baseline), and this stabilization of weight persisted over the 12-week study period. Total body water as a percentage of body weight remained stable, as did the proportion of patients with an acute-phase protein response, patients' nutritional intake, and performance status. Overall median survival from diagnosis in this study was 203 days. This study suggests that EPA is well tolerated, may stabilize weight in cachectic pancreatic cancer patients, and should be tested as an anticachectic agent in controlled trials. References 1.Wigmore, SJ, Plester, CE, Richardson, RA, Ross, JA, and Fearon, KCH: Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75, 106-109, 1997. 2.DeWys, WD, Begg, C, Lavin, PT, Band, PR, Bennett, JM, et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69, 491-497, 1980. 3.Oveson, L, Hannibal, J, and Mortensen, EL: The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 19, 159-167, 1993. 4.Ng, E-H, and Lowry, SF: Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 5, 161-184, 1991. 5.Moldawer, LL, and Copeland, EM: Proinflammatory cytokines, nutritional support, and the cachexia syndrome. Interactions and therapeutic options. Cancer 79, 1828-1839, 1997. 6.McNamara, MJ, Alexander, HR, and Norton, JA: Cytokines and their role in the pathophysiology of cancer cachexia. J Parent Enteral Nutr 16 Suppl, 50S-55S, 1992. 7.Falconer, JS, Fearon, KCH, Plester, CE, Ross, JA, and Carter, DC: Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219, 325-331, 1994. 8.Wigmore, SJ, Plester, CE, Ross, JA, and Fearon, KCH: Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 84, 196-197, 1997. 9.Falconer, JS, Fearon, KCH, Ross, JA, Elton, RE, Wigmore, SJ, et al.: The acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75, 2077-2082, 1995. 10.Heinrich, PC, Castell, JV, and Andus, T: Interleukin-6 and the acute phase response. Biochem J 265, 621-636, 1990. Vol. 36, No. 2 183 11.Endres, S, Ghorbani, R, Kelley, VE, Georgilis, K, Lonnemann, G, et al.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320, 265-271, 1989. 12.Wigmore, SJ, Fearon, KCH, Maingay, JP, and Ross, JA: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 92, 215-221, 1997. 13.Falconer, JS, Ross, JA, Fearon, KCH, Tisdale, MJ, Hawkins, AH, et al.: Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 69, 826-832, 1994. 14.Beck, SA, Smith, KL, and Tisdale, MJ: Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Can-cer Res 51, 6089-6093, 1991. 15.Tisdale, MJ: Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 12 Suppl, S31-S33, 1996. 16.Wigmore, SJ, Ross, JA, Falconer, JS, Plester, CE, Tisdale, MJ, et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12 Suppl, S27-S30, 1996. 17.Jelliffe, DB: The Assessment of the Nutritional Status of the Community. Geneva, Switzerland: World Health Organization, 1966. (WHO Monogr 53) 18.Hannan, WJ, Cowen, SJ, Plester, CE, Fearon, KCH, and de Beaux, AC: Comparison of bioimpedance spectroscopy and multi-frequency bioimpedance analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci 89, 651-658, 1995. 19.Cohn, SH, Vartsky, D, Vaswani, AN, Sawitsky, A, Rai, K, et al.: Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 4, 107-119, 1982. 20.Lai, PBS, Ross, JA, Fearon, KCH, Anderson, JD, and Carter, DC: Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 74, 1375-1383, 1996. 21.Todorov, P, Cariuk, P, McDevitt, T, Coles, B, Fearon, KCH, et al.: Characterization of a cancer cachectic factor. Nature 379, 739-742, 1996. 22.Mor, V: Cancer patients, quality of life over the disease course: lessons from the real world. J Chron Dis 40, 535-544, 1987. 23.Ahlgren, JD: Epidemiology and risk factors in pancreatic cancer. Semin Oncol 23, 241-250, 1996. 24.Fearon, KCH, Falconer, JS, Ross, JA, Carter, DC, Hunter, JO, et al.: An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gamma-linolenate. Anticancer Res 16, 867-874, 1996. 25.Leaf, A, and Weber, PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 318, 549-554, 1998. 26.Cersosimo, E, Pisters, PWT, Pesola, G, McDermott, K, Bajournas, D, et al.: Insulin secretion and actions in patients with pancreatic cancer. Cancer 67, 486-493, 1991. 27.Glauber, H, Wallace, P, Griver, K, and Brechtel, G: Adverse effect of -3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 108, 663-668, 1988. 28.Borkman, M, Chisholm, DJ, Furler, SM, Storlien, LH, Kraegen, EW, et al.: Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes 38, 1314-1319, 1989. 29.van Houwelingen, R, Nordøy, A, van der Beek, E, Houtsmuller, U, de Metz, M, et al.: Effect of a moderate fish intake on blood pressure, bleeding time, hematology and clinical chemistry in healthy males. Am J Clin Nutr 46, 424-436, 1987. 30.Clarke, JTR, Cullen-Dean, G, Regelink, E, Chan, L, and Rose, V: Increased incidence of epistaxis in adolescents with familial hypercholesterolemia treated with fish oil. J Pediatr 116, 139-141, 1990. 31.Calder, PC: Immunomodulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Proc Nutr Soc 55, 737-774, 1996. Cancer Res, May 2001 Lancet Oncology, 1/02 Br J Cancer, 11/02 Nutrition & Cancer, 9/03 Br J Cancer, 3/04 Cancer, 8/04 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.